Venetoclax and acute myeloid leukaemia: an expanding new frontier
Mené en Chine sur 33 patients adultes atteints d'une leucémie myéloïde aiguë (âge : 18-60 ans ; durée médiane de suivi : 11 mois), cet essai de phase II évalue l'efficacité, du point de vue du taux de rémission complète, et la toxicité d'une chimiothérapie d'induction combinant daunorubicine, cytarabine et vénétoclax
Venetoclax is an inhibitor of the anti-apoptotic B-cell lymphoma-2 (BCL-2) proteinthat has revolutionised the management of acute myeloid leukaemia in the past 5 years.Venetoclax in combination with azacitidine has become the new standard of care forthe majority of patients with acute myeloid leukaemia who are ineligible for intensivechemotherapy due to age, fitness, or comorbidities. Venetoclax has improved outcomes for this patient population and represents a valuablenew treatment option in this setting. There is now interest in studying venetoclaxcombined with other acute myeloid leukaemia treatment regimens, including intensivechemotherapy
The Lancet Haematology , commentaire, 2021